Top Section
Explore Business Standard
Don’t miss the latest developments in business and finance.
High blood pressure impairs one's breathing capacity by hardening the airways in the respiratory system, thereby increasing resistance, a study has found. However, being physically active can help by improving the functioning of respiratory muscles, resulting in better coordination between ventilation and blood flow in the lungs, researchers from the Federal University of Sao Paulo, Brazil, found. Hypertension, in which one's blood pressure remains unusually high, is known to thicken the blood vessels and harden the arteries. The researchers said that something similar happens with the bronchi -- branches of the main windpipe (trachea) -- in the respiratory system as well. "This is very important as the more hardened the bronchi becomes, the more difficult it becomes for air to enter and leave the lungs. In the long run, this accelerated process of hardening of the bronchi makes breathing difficult for older people. Worse still, it's a cycle: lower oxygen saturation accelerates the
World Hypertension Day 2024: This day is celebrated every year to raise awareness about the risk of hypertension and its preventive measures. Here's all you need to know about this day
Glenmark Pharmaceuticals is recalling 6,528 bottles of a medication used to treat high blood pressure in the American market due to failed dissolution specifications, the US health regulator said. The US-based arm of the Mumbai-headquartered drug firm is recalling the affected lot of Diltiazem Hydrochloride extended-release capsules, the US Food and Drug Administration said in its latest Enforcement Report. The affected lot has been produced in India and is being recalled by New Jersey-based Glenmark Pharmaceuticals Inc for "failed dissolution specifications", the USFDA said. "Out of Specification (OOS) was reported in a test of dissolution at the 12th month time point in long-term stability study," it noted. Glenmark initiated Class II recall of the drug across the US on March 26 this year. As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences
This is the first study to compare the development and risk factors associated with persistent high blood pressure in people with Covid-19 infection to influenza, a similar respiratory virus
Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator to market its generic Metoprolol Succinate extended-release tablets used for lowering blood pressure. The approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application is for Metoprolol Succinate extended-release tablets of strengths 25 mg, 50 mg, 100 mg, and 200 mg, Lupin said in a regulatory filing. These are generic equivalent of Toprol-XL Tablets of Sequel Therapeutics, LLC. This product will be manufactured at Lupin's Pithampur facility in India, the company said. Metoprolol Succinate extended-release tablets had an estimated annual sales of USD 305 million in the US, the company said citing IQVIA MAT June 2023 data.
World hypertension day is observed on May 17 every year. Read more about its history, theme and exercises to combat high blood pressure
Drug firm Granules India on Monday said it has received approval from the US health regulator to market a generic product to treat high blood pressure. The company has received approval from the US Food & Drug Administration (USFDA) to market Losartan Potassium tablets in strengths of 25 mg, 50 mg, and 100 mg, Granules India said in a regulatory filing. The Hyderabad-based company's product is bioequivalent to the Organon LLC's Cozaar tablets. According to IQVIA/IMS Health, the current annual US market for Losartan potassium tablets is around USD 336 million. Shares of the company were trading 1.24 per cent down at Rs 281.75 apiece on the BSE.
More than 50 per cent of patients in India are unaware of their high blood pressure, finds a study published in Lancet Regional Health Journal
The tentative approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application (ANDA) Azilsartan Medoxomil tablets is for strengths of 40 mg and 80 mg
The specified batch, which is being recalled, has been manufactured at Unichem's Goa-based facility
Women who were hypertensive at an average age of 44 had a 68% higher risk for dementia than those who had normal blood pressure at that age
Drug carvedilol can protect against the sun-induced cell damage that leads to skin cancer
As many as 100% of patients on trial saw their blood levels drop below 140 over 90